CINTIA CERCATO

(Fonte: Lattes)
Índice h a partir de 2011
13
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/10 - Laboratório de Lípides, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Assunto: Bariatric surgery ×

Resultados de Busca

Agora exibindo 1 - 5 de 5
  • article 53 Citação(ões) na Scopus
    Tratamento de curto prazo com liraglutide no reganho de peso após cirurgia bariátrica
    (2013) PAJECKI, Denis; HALPERN, Alfredo; CERCATO, Cintia; MANCINI, Marcio; CLEVA, Roberto de; SANTO, Marco Aurélio
    OBJECTIVE: To evaluate the results of the use of liraglutide in a group of patients undergoing surgical treatment of morbid obesity with unsatisfactory weight loss or regain of more than 15% of minimum reached weight. METHODS: The authors conducted a retrospective analysis of 15 operated patients who had excess weight loss <50% after two years of follow-up or regained weight more than 15% of the minimum reached weight. We included only patients who had the expected ""surgical anatomy"", assessed by contrast radiography and endoscopy. Mean age was 47.2 ± 12.5 years, and patients received liraglutide at doses from 1.2 to 3.0 mg/day for eight to 28 weeks follow-up. RESULTS: Surgical treatment induced a weight loss of 34.1 ± 16.5 kg. The average weight regain after 5.3 ± 3.3 years was 14.2 ± 12.1 Kg. The average weight was significantly reduced after treatment with liraglutide (100.9 ± 18.3 kg. vs Kg 93.5 ± 17.4, p <0.0001). Six patients had nausea and two discontinued therapy due to the cost of medication. CONCLUSION: medical treatment directed to the control of satiety using liraglutide may be an alternative treatment of patients with poor weight loss or weight regain after surgery when no technical problem has been identified.
  • article 9 Citação(ões) na Scopus
    Pharmacokinetics of oral levonorgestrel and ethinylestradiol in women after Roux-en-Y gastric bypass surgery
    (2021) BRITO, Claudia Moreira de; MELO, Maria Edna de; MANCINI, Marcio C.; SANTO, Marco Aurelio; CERCATO, Cintia
    Background: Most patients undergoing Roux-en-Y gastric bypass (RYGB) are women in reproductive age. It is not known if bariatric surgery affects the pharmacokinetics of oral contraceptives. Objectives: The primary objective was to evaluate ethinylestradiol (EE) and levonorgestrel (LNG) absorption in women undergoing RYGB, compared with nonoperated controls matched by age and body mass index (BMI). A secondary objective was to assess whether the time since surgery and BMI in the postoperative period influenced the absorption parameters. Setting: University hospital, Brazil. Methods: This study was designed to compare the maximum plasma concentration (C-max), the time to the peak plasma level (T-max), the area under the curve (AUC(0-8) and AUC(0-infinity)) after a single dose of a combined oral contraceptive with 0.03 mg EE and 0.15 mg LNG among 20 women after RYGB and 20 controls. Blood samples were obtained for 8 hours. Results: The mean LNG AUC(0-8) and LNG AUC(0-infinity) were higher in RYGB group (P = .048 and P = .004, respectively). We found a positive correlation for LNG AUC(0-8) (P = .045) and AUC(0-infinity) (P = .004) and the time since surgery, and we found a negative correlation for LNG Cmax (P = .018), AUC(0-8) (P = .003), and AUC(0-infinity) (P = .001) and BMI. Conclusion: No significant differences were found in oral EE pharmacokinetics. The operated group showed higher mean LNG AUC(0-8) and AUC(0-infinity) but it was not considered clinically significant. The present study suggests that RYGB may not affect EE and LNG absorption.
  • article 6 Citação(ões) na Scopus
  • article 0 Citação(ões) na Scopus
    Treatment with Antiobesity Drugs in Weight Regain After Bariatric Surgery: a Retrospective Cohort Study
    (2023) BOGER, Bibiana S.; QUEIROZ, Nara L.; NORIEGA, Paulo E. P.; CANUTO, Maicon C.; STUMPF, Matheo A. M.; CERCATO, Cintia; MANCINI, Marcio C.; MELO, Maria E. de
    Background Bariatric surgery is the most efficient treatment for obesity. However, in some cases, weight regain can occur. Currently, it is unknown the best antiobesity medication (AOM) for such clinical situation. This study aims to evaluate the effect of AOM in patients with weight regain after bariatric surgery. Methods A retrospective cohort study from December 2010 to July 2019 with patients submitted to bariatric surgery that had weight regain and received AOM for at least 2 years. Results Of 96 patients that had weight regain in the analyzed period and received AOM, 16 were excluded from the analysis due to non-compliance (n = 7), treatment failure (n = 5), intolerable side effects with all available AOM (n = 2), or interaction with other medications (n = 2). Eighty patients were included in the analysis. The mean age was 59.0 +/- 10.1 years, 88.8% were female, 91.2% white, and most of them were submitted to gastric bypass (87.6%). The mean preoperative and nadir weight after surgery were 127.9 +/- 25.5 kg and 84.7 +/- 22.8 kg, respectively. At the initiation of AOM, the mean baseline weight was 99.4 +/- 23.1 kg. After 2 years of follow-up, there was significant weight loss in the groups treated with topiramate-alone (- 3.2 kg), topiramate plus sibutramine (- 6.1kg), and orlistat-alone or in combination (- 3.9kg). No statistical difference was observed in the sibutramine- alone group. Conclusion Topiramate (alone or associated with sibutramine) and orlistat (alone or in combination) promoted significant weight loss after 2 years of use in patients submitted to bariatric surgery with weight regain.
  • article 0 Citação(ões) na Scopus
    Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity
    (2023) STUMPF, Matheo A. M.; CERCATO, Cintia; MELO, Maria E. de; SANTOS, Raul D.; MANCINI, Marcio C.
    Obesity is a prevalent chronic disorder and a well-known risk factor for cardiovascular disease. However, the evidence of treating obesity for primary prevention of major cardiovascular events is still scarce and controversial. In this review, we provided a comprehensive description of the current evidence in treating obesity regarding cardiovascular protection. Bariatric surgery appears to be the most robust method to reduce events in people without established cardiovascular disease. High compliance to lifestyle interventions can further reduce cardiovascular risk. Concerning pharmacological therapies, a post hoc analysis from SUSTAIN-6 and a meta-analysis from STEP trials suggest that semaglutide, a GLP-1 receptor agonist, could reduce cardiovascular events in people without established cardiovascular disease. The first study addressed specifically a high-risk population with diabetes and, the second, low- or intermediary-risk individuals without diabetes. Tirzepatide, a novel dual GIP/GLP-1 agonist, although not yet tested in specific cardiovascular outcomes trials, could be an alternative since it induces loss in weight similar to the achieved by bariatric surgery. Therefore, extrapolated data in distinct baseline cardiovascular risk populations suggest that these two drugs could be used in primary prevention with the aim of preventing cardiovascular events, but the grade of this evidence is still low. Specifically designed studies are needed to address this specific topic.